Form 4: Elicio Therapeutics Director Acquires $20 Million Convertible Note

Yekaterina Chudnovsky, a director and 10% owner of Elicio Therapeutics, acquired a $20 million convertible note through GKCC, LLC, convertible into approximately 3,442,341 shares of common stock.

Summary

• On August 12, 2024, GKCC, LLC, purchased a convertible note from Elicio Therapeutics for $20 million.
• The convertible note can be converted into approximately 3,442,341 shares of common stock at a conversion price of $5.81 per share.
• The note matures on February 15, 2026, and accrues interest at 3% per annum, payable quarterly.
• Yekaterina Chudnovsky, a director and 10% owner of Elicio Therapeutics, is the sole member and manager of GKCC, LLC, and may be deemed to beneficially own the shares held by GKCC, LLC.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard financial transaction. The impact on the company depends on the future performance and the conversion of the note.

Positives

• The $20 million investment provides Elicio Therapeutics with additional capital.

Risks

• The conversion of the note could dilute existing shareholders' equity.

Future Outlook

The convertible note provides Elicio Therapeutics with capital, but its conversion could impact the company's capital structure and shareholder equity.

Management Comments

• Yekaterina (Katie) Chudnovsky is the sole member and manager of the Purchaser and may be deemed to beneficially own the shares held by the Purchaser.

Industry Context

Convertible notes are a common financing tool for biotech companies, allowing them to raise capital without immediately diluting existing shareholders. The terms of the note, such as the conversion price and interest rate, are crucial in determining its attractiveness to both the issuer and the investor.

Comparison to Industry Standards

• The 3% interest rate on the convertible note is relatively standard for biotech companies of this size.
• The conversion price of $5.81 will be compared to the market price of ELTX stock to determine the value of the note.

Stakeholder Impact

• Shareholders may experience dilution if the convertible note is converted into common stock.
• The company's financial stability is improved by the $20 million investment.

Key Dates